Huntington's disease is a genetic neurodegenerative disorder that affects both motor and cognitive function and gradually reduces the independence and quality of life of those affected. One of the ...

Chorea Huntington (known as "Veitstanz" in German) is a rare brain disorder that causes uncontrollable, jerky movements in individuals. Photo: Getty Images/Science Photo Library RF Huntington’s ...

Please provide your email address to receive an email when new articles are posted on . According to a release from Neurocrine Biosciences Inc., the selective vesicular monoamine transporter 2 ...

Neurocrine Biosciences today announced positive top-line data from its Phase 3 KINECT-HD study evaluating the efficacy, safety and tolerability of valbenazine, a selective vesicular monoamine ...

People with uncontrolled movement problems can have a harder time doing everyday tasks such as speaking, reading, writing, and cooking, which can cause a loss of independence. This may cause people to ...

‌Chorea is a movement disorder that stems from something wrong with the basal ganglia nerve structure deep in your brain. It causes involuntary movements of the hands, feet, and face. These movements ...

Many people with Huntington’s disease experience chorea, but they are separate conditions. Chorea is one of several common symptoms of Huntington’s disease, but it has other potential causes. Chorea ...

The drug valbenazine statistically improves chorea, a movement disorder commonly associated with Huntington's disease, when compared to a placebo. The drug valbenazine statistically improves chorea, a ...

A drug widely available in Europe and Canada – but not the United States – dramatically eases one of the most disabling symptoms of Huntington’s disease, involuntary writhing movements known as chorea ...

Huntington’s disease, also known as Huntington’s chorea and formerly called “Saint Vitus’ dance,” is a rare, hereditary disorder of the central nervous system. It is characterized by jerky movements ...

Neurocrine Biosciences announced data from a phase 3 trial of Ingrezza that showed it reduced chorea severity among patients with Huntington’s disease. The trial, called KINECT-HD, examined the ...